Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.

Josephine A. Taverna, Adam Lerner, Jag Bhawan, Marie France Demierre

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions. The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.

Original languageEnglish (US)
Pages (from-to)731-732
Number of pages2
JournalJournal of drugs in dermatology : JDD
Volume6
Issue number7
StatePublished - Jul 2007
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.'. Together they form a unique fingerprint.

Cite this